Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025